Boothbay Fund Management’s Ocular Therapeutix OCUL Stock Holding History

Boothbay Fund Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.83M	Buy	186,356 +53,724	+41%	+$487K	0.02%	768
2026 Q1	$1.12M	Buy	+132,632	New	+$1.26M	0.01%	892
2023 Q3	–	Sell	-17,880	Closed	-$92.3K	–	1973
2023 Q2	$92.3K	Sell	17,880 -17,880	-50%	-$106K	﹤0.01%	1629
2023 Q1	$188K	Hold	35,760	–	–	﹤0.01%	1763
2022 Q4	$100K	Sell	35,760 -11,621	-25%	-$38.5K	﹤0.01%	1784
2022 Q3	$197K	Buy	+47,381	New	+$239K	﹤0.01%	1857
2021 Q4	–	Sell	-41,466	Closed	-$415K	–	2118
2021 Q3	$415K	Sell	41,466 -8,459	-17%	-$95K	0.01%	1174
2021 Q2	$708K	Buy	49,925 +7,748	+18%	+$118K	0.02%	853
2021 Q1	$692K	Sell	42,177 -26,669	-39%	-$514K	0.03%	770
2020 Q4	$1.43M	Sell	68,846 -102,889	-60%	-$1.53M	0.05%	370
2020 Q3	$1.31M	Sell	171,735 -78,977	-32%	-$655K	0.08%	348
2020 Q2	$2.09M	Buy	250,712 +64,763	+35%	+$429K	0.14%	192
2020 Q1	$920K	Buy	185,949 +96,872	+109%	+$478K	0.08%	322
2019 Q4	$352K	Sell	89,077 -1,450	-2%	-$5.04K	0.03%	574
2019 Q3	$275K	Buy	90,527 +73,966	+447%	+$331K	0.03%	597
2019 Q2	$73K	Buy	+16,561	New	+$61.3K	0.01%	675

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Boothbay Fund Management's OCUL Position: Q2 2026 in Review

Boothbay Fund Management increased its Ocular Therapeutix (OCUL) stake by 41% in Q2 2026, buying an estimated $487K and bringing the position to 186,356 shares worth $1.83M. The position accounts for 0.02% of the portfolio, ranked #768.

Boothbay Fund Management first reported a position in OCUL in Q2 2019 and has held it in 16 quarters since. The position peaked at $2.09M in Q2 2020. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Boothbay Fund Management held 186,356 shares of Ocular Therapeutix worth $1.83M as of Q2 2026.
Boothbay Fund Management bought 53,724 Ocular Therapeutix shares in Q2 2026, an estimated $487K.
Ocular Therapeutix made up 0.02% of Boothbay Fund Management's portfolio in Q2 2026, its #768 holding.
Boothbay Fund Management first reported a position in Ocular Therapeutix in Q2 2019 and has held it in 16 quarters since.
Boothbay Fund Management's Ocular Therapeutix position peaked at $2.09M in Q2 2020.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.